BioCentury | Apr 22, 2019
Distillery Therapeutics

Inhibiting the LLGL2-SLC7A5-YKT6 complex for breast cancer

...of breast cancer. J-Pharma Co. Ltd. has JPH203 in Phase I testing for solid tumors. Therapeia GmbH & Co. KG...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

...and testing inhibitors of SLC7A5 or SLC43A1 in models of MYC-driven neuroblastoma and Burkitt’s lymphoma. Therapeia GmbH & Co. KG...
BioCentury | Feb 3, 2017
Company News

Therapeia, Telix deal

...Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia...
...includes milestones and royalties but declined to provide specifics. Therapeia did not respond to inquiries. Therapeia GmbH & Co. KG...
...North Melbourne, Australia Business: Cancer Shannon Lehnbeuter Telix Pharmaceuticals Ltd. Solute carrier family 7 member 5 (SLC7A5) (LAT1) ACD-101 Therapeia...
Items per page:
1 - 3 of 3
BioCentury | Apr 22, 2019
Distillery Therapeutics

Inhibiting the LLGL2-SLC7A5-YKT6 complex for breast cancer

...of breast cancer. J-Pharma Co. Ltd. has JPH203 in Phase I testing for solid tumors. Therapeia GmbH & Co. KG...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

...and testing inhibitors of SLC7A5 or SLC43A1 in models of MYC-driven neuroblastoma and Burkitt’s lymphoma. Therapeia GmbH & Co. KG...
BioCentury | Feb 3, 2017
Company News

Therapeia, Telix deal

...Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia...
...includes milestones and royalties but declined to provide specifics. Therapeia did not respond to inquiries. Therapeia GmbH & Co. KG...
...North Melbourne, Australia Business: Cancer Shannon Lehnbeuter Telix Pharmaceuticals Ltd. Solute carrier family 7 member 5 (SLC7A5) (LAT1) ACD-101 Therapeia...
Items per page:
1 - 3 of 3